Astellas Agrees to Buy Audentes in $3 Billion Gene-Therapy Deal

(Bloomberg) -- Astellas Pharma Inc. agreed to buy Audentes Therapeutics Inc. for about $3 billion, the latest deal by a pharmaceutical company eager to push into promising gene-therapy technologies.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.